ID   CBL_MOUSE               Reviewed;         913 AA.
AC   P22682; Q3U527; Q8CEA1;
DT   01-AUG-1991, integrated into UniProtKB/Swiss-Prot.
DT   27-JUL-2011, sequence version 3.
DT   18-JUN-2025, entry version 228.
DE   RecName: Full=E3 ubiquitin-protein ligase CBL;
DE            EC=2.3.2.27 {ECO:0000269|PubMed:12649282, ECO:0000269|PubMed:20100865};
DE   AltName: Full=Casitas B-lineage lymphoma proto-oncogene;
DE   AltName: Full=Proto-oncogene c-Cbl;
DE   AltName: Full=RING-type E3 ubiquitin transferase CBL {ECO:0000305};
DE   AltName: Full=Signal transduction protein CBL;
GN   Name=Cbl;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND MUTANT 70Z/3.
RX   PubMed=2030914;
RA   Blake T.J., Shapiro M., Morse H.C. III, Langdon W.Y.;
RT   "The sequences of the human and mouse c-cbl proto-oncogenes show v-cbl was
RT   generated by a large truncation encompassing a proline-rich domain and a
RT   leucine zipper-like motif.";
RL   Oncogene 6:653-657(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6J, and NOD; TISSUE=Skin, and Thymus;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M., Davis M.J.,
RA   Wilming L.G., Aidinis V., Allen J.E., Ambesi-Impiombato A., Apweiler R.,
RA   Aturaliya R.N., Bailey T.L., Bansal M., Baxter L., Beisel K.W., Bersano T.,
RA   Bono H., Chalk A.M., Chiu K.P., Choudhary V., Christoffels A.,
RA   Clutterbuck D.R., Crowe M.L., Dalla E., Dalrymple B.P., de Bono B.,
RA   Della Gatta G., di Bernardo D., Down T., Engstrom P., Fagiolini M.,
RA   Faulkner G., Fletcher C.F., Fukushima T., Furuno M., Futaki S.,
RA   Gariboldi M., Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N., Hill D.,
RA   Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T., Jakt M.,
RA   Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H., Kitano H.,
RA   Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K., Kurochkin I.V.,
RA   Lareau L.F., Lazarevic D., Lipovich L., Liu J., Liuni S., McWilliam S.,
RA   Madan Babu M., Madera M., Marchionni L., Matsuda H., Matsuzawa S., Miki H.,
RA   Mignone F., Miyake S., Morris K., Mottagui-Tabar S., Mulder N., Nakano N.,
RA   Nakauchi H., Ng P., Nilsson R., Nishiguchi S., Nishikawa S., Nori F.,
RA   Ohara O., Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G.,
RA   Pesole G., Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z.,
RA   Ringwald M., Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B., Sperling S.,
RA   Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K., Tammoja K.,
RA   Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A., Ueda H.R.,
RA   van Nimwegen E., Verardo R., Wei C.L., Yagi K., Yamanishi H.,
RA   Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C., Grimmond S.M.,
RA   Teasdale R.D., Liu E.T., Brusic V., Quackenbush J., Wahlestedt C.,
RA   Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y., Fukuda S.,
RA   Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T., Iida J., Imamura K.,
RA   Itoh M., Kato T., Kawaji H., Kawagashira N., Kawashima T., Kojima M.,
RA   Kondo S., Konno H., Nakano K., Ninomiya N., Nishio T., Okada M., Plessy C.,
RA   Shibata K., Shiraki T., Suzuki S., Tagami M., Waki K., Watahiki A.,
RA   Okamura-Oho Y., Suzuki H., Kawai J., Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   INTERACTION WITH LYN, AND PHOSPHORYLATION.
RX   PubMed=7782294; DOI=10.1074/jbc.270.24.14347;
RA   Tanaka S., Neff L., Baron R., Levy J.B.;
RT   "Tyrosine phosphorylation and translocation of the c-cbl protein after
RT   activation of tyrosine kinase signaling pathways.";
RL   J. Biol. Chem. 270:14347-14351(1995).
RN   [5]
RP   PHOSPHORYLATION BY SYK.
RX   PubMed=8798454; DOI=10.1074/jbc.271.37.22782;
RA   Latour S., Chow L.M., Veillette A.;
RT   "Differential intrinsic enzymatic activity of Syk and Zap-70 protein-
RT   tyrosine kinases.";
RL   J. Biol. Chem. 271:22782-22790(1996).
RN   [6]
RP   PHOSPHORYLATION BY ZAP70.
RX   PubMed=8551236; DOI=10.1084/jem.183.1.301;
RA   Fournel M., Davidson D., Weil R., Veillette A.;
RT   "Association of tyrosine protein kinase Zap-70 with the protooncogene
RT   product p120c-cbl in T lymphocytes.";
RL   J. Exp. Med. 183:301-306(1996).
RN   [7]
RP   INTERACTION WITH FLT1.
RX   PubMed=9722576; DOI=10.1074/jbc.273.36.23410;
RA   Ito N., Wernstedt C., Engstrom U., Claesson-Welsh L.;
RT   "Identification of vascular endothelial growth factor receptor-1 tyrosine
RT   phosphorylation sites and binding of SH2 domain-containing molecules.";
RL   J. Biol. Chem. 273:23410-23418(1998).
RN   [8]
RP   INTERACTION WITH SORBS1.
RX   PubMed=9447983; DOI=10.1128/mcb.18.2.872;
RA   Ribon V., Printen J.A., Hoffman N.G., Kay B.K., Saltiel A.R.;
RT   "A novel, multifunctional c-Cbl binding protein in insulin receptor
RT   signaling in 3T3-L1 adipocytes.";
RL   Mol. Cell. Biol. 18:872-879(1998).
RN   [9]
RP   FUNCTION.
RX   PubMed=9653117; DOI=10.1073/pnas.95.14.7927;
RA   Miyake S., Lupher M.L. Jr., Druker B., Band H.;
RT   "The tyrosine kinase regulator Cbl enhances the ubiquitination and
RT   degradation of the platelet-derived growth factor receptor alpha.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:7927-7932(1998).
RN   [10]
RP   PHOSPHORYLATION BY HCK, AND INTERACTION WITH HCK.
RX   PubMed=10092522; DOI=10.1006/bbrc.1999.0427;
RA   Howlett C.J., Bisson S.A., Resek M.E., Tigley A.W., Robbins S.M.;
RT   "The proto-oncogene p120(Cbl) is a downstream substrate of the Hck protein-
RT   tyrosine kinase.";
RL   Biochem. Biophys. Res. Commun. 257:129-138(1999).
RN   [11]
RP   FUNCTION.
RX   PubMed=10393178; DOI=10.1093/emboj/18.13.3616;
RA   Lee P.S., Wang Y., Dominguez M.G., Yeung Y.G., Murphy M.A., Bowtell D.D.,
RA   Stanley E.R.;
RT   "The Cbl protooncoprotein stimulates CSF-1 receptor multiubiquitination and
RT   endocytosis, and attenuates macrophage proliferation.";
RL   EMBO J. 18:3616-3628(1999).
RN   [12]
RP   INTERACTION WITH SLA2 AND ZAP70, AND MUTAGENESIS OF GLY-304.
RX   PubMed=12024036; DOI=10.1128/mcb.22.12.4241-4255.2002;
RA   Loreto M.P., Berry D.M., McGlade C.J.;
RT   "Functional cooperation between c-Cbl and Src-like adaptor protein 2 in the
RT   negative regulation of T-cell receptor signaling.";
RL   Mol. Cell. Biol. 22:4241-4255(2002).
RN   [13]
RP   INTERACTION WITH KDR, FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=12649282; DOI=10.1074/jbc.m301410200;
RA   Duval M., Bedard-Goulet S., Delisle C., Gratton J.P.;
RT   "Vascular endothelial growth factor-dependent down-regulation of Flk-1/KDR
RT   involves Cbl-mediated ubiquitination. Consequences on nitric oxide
RT   production from endothelial cells.";
RL   J. Biol. Chem. 278:20091-20097(2003).
RN   [14]
RP   INTERACTION WITH CBLB.
RX   PubMed=12842890; DOI=10.1074/jbc.m300664200;
RA   Liu J., DeYoung S.M., Hwang J.B., O'Leary E.E., Saltiel A.R.;
RT   "The roles of Cbl-b and c-Cbl in insulin-stimulated glucose transport.";
RL   J. Biol. Chem. 278:36754-36762(2003).
RN   [15]
RP   INTERACTION WITH FLT1 AND CD2AP, AND PHOSPHORYLATION IN RESPONSE TO VEGFA.
RX   PubMed=15001553; DOI=10.1096/fj.03-0767fje;
RA   Kobayashi S., Sawano A., Nojima Y., Shibuya M., Maru Y.;
RT   "The c-Cbl/CD2AP complex regulates VEGF-induced endocytosis and degradation
RT   of Flt-1 (VEGFR-1).";
RL   FASEB J. 18:929-931(2004).
RN   [16]
RP   PHOSPHORYLATION, AND INTERACTION WITH SLA2 AND CSF1R.
RX   PubMed=17353186; DOI=10.1074/jbc.m701182200;
RA   Pakuts B., Debonneville C., Liontos L.M., Loreto M.P., McGlade C.J.;
RT   "The Src-like adaptor protein 2 regulates colony-stimulating factor-1
RT   receptor signaling and down-regulation.";
RL   J. Biol. Chem. 282:17953-17963(2007).
RN   [17]
RP   INTERACTION WITH PDGFRB.
RX   PubMed=17620338; DOI=10.1074/jbc.m701797200;
RA   Reddi A.L., Ying G., Duan L., Chen G., Dimri M., Douillard P., Druker B.J.,
RA   Naramura M., Band V., Band H.;
RT   "Binding of Cbl to a phospholipase Cgamma1-docking site on platelet-derived
RT   growth factor receptor beta provides a dual mechanism of negative
RT   regulation.";
RL   J. Biol. Chem. 282:29336-29347(2007).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-666; SER-667 AND TYR-672, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Mast cell;
RX   PubMed=17947660; DOI=10.4049/jimmunol.179.9.5864;
RA   Cao L., Yu K., Banh C., Nguyen V., Ritz A., Raphael B.J., Kawakami Y.,
RA   Kawakami T., Salomon A.R.;
RT   "Quantitative time-resolved phosphoproteomic analysis of mast cell
RT   signaling.";
RL   J. Immunol. 179:5864-5876(2007).
RN   [19]
RP   INTERACTION WITH ATX2.
RX   PubMed=18602463; DOI=10.1016/j.cellsig.2008.05.018;
RA   Nonis D., Schmidt M.H., van de Loo S., Eich F., Dikic I., Nowock J.,
RA   Auburger G.;
RT   "Ataxin-2 associates with the endocytosis complex and affects EGF receptor
RT   trafficking.";
RL   Cell. Signal. 20:1725-1739(2008).
RN   [20]
RP   INTERACTION WITH EPHB1, AND PHOSPHORYLATION.
RX   PubMed=18034775; DOI=10.1111/j.1600-0854.2007.00679.x;
RA   Fasen K., Cerretti D.P., Huynh-Do U.;
RT   "Ligand binding induces Cbl-dependent EphB1 receptor degradation through
RT   the lysosomal pathway.";
RL   Traffic 9:251-266(2008).
RN   [21]
RP   FUNCTION IN UBIQUITINATION OF KIT, AND PHOSPHORYLATION.
RX   PubMed=19265199; DOI=10.1074/jbc.m808058200;
RA   Sun J., Pedersen M., Ronnstrand L.;
RT   "The D816V mutation of c-Kit circumvents a requirement for Src family
RT   kinases in c-Kit signal transduction.";
RL   J. Biol. Chem. 284:11039-11047(2009).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-617; SER-640 AND SER-692, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Brain, Heart, Kidney, Lung, Spleen, and Testis;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and expression.";
RL   Cell 143:1174-1189(2010).
RN   [23]
RP   FUNCTION IN UBIQUITINATION OF EPHA8, AND CATALYTIC ACTIVITY.
RX   PubMed=20100865; DOI=10.1128/mcb.01605-09;
RA   Kim J., Lee H., Kim Y., Yoo S., Park E., Park S.;
RT   "The SAM domains of Anks family proteins are critically involved in
RT   modulating the degradation of EphA receptors.";
RL   Mol. Cell. Biol. 30:1582-1592(2010).
RN   [24]
RP   INTERACTION WITH SH3KBP1.
RX   PubMed=21830225; DOI=10.1002/cbf.1792;
RA   Feng L., Wang J.T., Jin H., Qian K., Geng J.G.;
RT   "SH3KBP1-binding protein 1 prevents epidermal growth factor receptor
RT   degradation by the interruption of c-Cbl-CIN85 complex.";
RL   Cell Biochem. Funct. 29:589-596(2011).
RN   [25]
RP   INTERACTION WITH SIGLEC10.
RX   PubMed=23374343; DOI=10.1016/j.cell.2013.01.011;
RA   Chen W., Han C., Xie B., Hu X., Yu Q., Shi L., Wang Q., Li D., Wang J.,
RA   Zheng P., Liu Y., Cao X.;
RT   "Induction of Siglec-G by RNA viruses inhibits the innate immune response
RT   by promoting RIG-I degradation.";
RL   Cell 152:467-478(2013).
RN   [26]
RP   INTERACTION WITH SH3KBP1.
RX   PubMed=29589748; DOI=10.1021/acs.biochem.8b00057;
RA   Li Q., Yang W., Wang Y., Liu W.;
RT   "Biochemical and Structural Studies of the Interaction between ARAP1 and
RT   CIN85.";
RL   Biochemistry 57:2132-2139(2018).
RN   [27]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=29237719; DOI=10.1083/jcb.201611050;
RA   Schmid F.M., Schou K.B., Vilhelm M.J., Holm M.S., Breslin L., Farinelli P.,
RA   Larsen L.A., Andersen J.S., Pedersen L.B., Christensen S.T.;
RT   "IFT20 modulates ciliary PDGFRalpha signaling by regulating the stability
RT   of Cbl E3 ubiquitin ligases.";
RL   J. Cell Biol. 217:151-161(2018).
CC   -!- FUNCTION: E3 ubiquitin-protein ligase that acts as a negative regulator
CC       of many signaling pathways by mediating ubiquitination of cell surface
CC       receptors (PubMed:10393178, PubMed:12649282, PubMed:19265199,
CC       PubMed:20100865, PubMed:9653117). Accepts ubiquitin from specific E2
CC       ubiquitin-conjugating enzymes, and then transfers it to substrates
CC       promoting their degradation by the proteasome (PubMed:12649282,
CC       PubMed:20100865). Recognizes activated receptor tyrosine kinases,
CC       including KIT, FLT1, FGFR1, FGFR2, PDGFRA, PDGFRB, CSF1R, EPHA8 and KDR
CC       and mediates their ubiquitination to terminate signaling
CC       (PubMed:19265199). Recognizes membrane-bound HCK, SRC and other kinases
CC       of the SRC family and mediates their ubiquitination and degradation (By
CC       similarity). Ubiquitinates EGFR and SPRY2 (By similarity).
CC       Ubiquitinates NECTIN1 following association between NECTIN1 and herpes
CC       simplex virus 1/HHV-1 envelope glycoprotein D, leading to NECTIN1
CC       removal from cell surface (By similarity). Participates in signal
CC       transduction in hematopoietic cells (By similarity). Plays an important
CC       role in the regulation of osteoblast differentiation and apoptosis (By
CC       similarity). Essential for osteoclastic bone resorption (By
CC       similarity). The 'Tyr-731' phosphorylated form induces the activation
CC       and recruitment of phosphatidylinositol 3-kinase to the cell membrane
CC       in a signaling pathway that is critical for osteoclast function (By
CC       similarity). May be functionally coupled with the E2 ubiquitin-protein
CC       ligase UB2D3 (By similarity). In association with CBLB, required for
CC       proper feedback inhibition of ciliary platelet-derived growth factor
CC       receptor-alpha (PDGFRA) signaling pathway via ubiquitination and
CC       internalization of PDGFRA (PubMed:29237719).
CC       {ECO:0000250|UniProtKB:P22681, ECO:0000269|PubMed:10393178,
CC       ECO:0000269|PubMed:12649282, ECO:0000269|PubMed:19265199,
CC       ECO:0000269|PubMed:20100865, ECO:0000269|PubMed:29237719,
CC       ECO:0000269|PubMed:9653117}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=S-ubiquitinyl-[E2 ubiquitin-conjugating enzyme]-L-cysteine +
CC         [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L-
CC         cysteine + N(6)-ubiquitinyl-[acceptor protein]-L-lysine.;
CC         EC=2.3.2.27; Evidence={ECO:0000269|PubMed:12649282,
CC         ECO:0000269|PubMed:20100865};
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC       {ECO:0000269|PubMed:12649282, ECO:0000269|PubMed:20100865}.
CC   -!- SUBUNIT: Forms homodimers; IFT20 promotes the formation of stable
CC       homodimers (By similarity). Interacts (phosphorylated) with PIK3R1.
CC       Interacts with phosphorylated LAT2 (By similarity). Associates with NCK
CC       via its SH3 domain. The phosphorylated C-terminus interacts with CD2AP
CC       via its second SH3 domain. Binds to UBE2L3. Interacts with adapters
CC       SLA, SLA2 and with the phosphorylated C-terminus of SH2B2. Interacts
CC       with EGFR, SYK and ZAP70 via the highly conserved Cbl-N region.
CC       Interacts with FGR. Also interacts with BLK, SORBS1 and INPPL1/SHIP2.
CC       Interacts with CBLB. Interacts with TEK/TIE2 (tyrosine phosphorylated)
CC       (By similarity). Interacts with ALK, AXL and FGFR2. Interacts with
CC       CSF1R, EPHB1, FLT1, KDR, PDGFRA and PDGFRB; regulates receptor
CC       degradation through ubiquitination. Interacts with HCK and LYN.
CC       Interacts with ATX2 (PubMed:18602463). Interacts with SH3KBP1 and this
CC       interaction is inhibited in the presence of SHKBP1 or ARAP1
CC       (PubMed:21830225, PubMed:29589748). Interacts with SIGLEC10
CC       (PubMed:23374343). Interacts with IFT20 (By similarity). Interacts with
CC       SPRY2; the interaction inhibits CBL-mediated ubiquitination of EGFR (By
CC       similarity). Interacts (phosphorylated at Tyr-780) with tensin TNS4
CC       (via SH2 domain); the interaction is enhanced in the presence of EGF
CC       and reduces interaction of CBL with EGFR (By similarity). Interacts
CC       with EGFR; the interaction is reduced in the presence of TNS4 (By
CC       similarity). Interacts with CD5 (By similarity). Interacts with CD93
CC       (By similarity). {ECO:0000250|UniProtKB:P22681,
CC       ECO:0000269|PubMed:10092522, ECO:0000269|PubMed:12024036,
CC       ECO:0000269|PubMed:12649282, ECO:0000269|PubMed:12842890,
CC       ECO:0000269|PubMed:15001553, ECO:0000269|PubMed:17353186,
CC       ECO:0000269|PubMed:17620338, ECO:0000269|PubMed:18034775,
CC       ECO:0000269|PubMed:18602463, ECO:0000269|PubMed:21830225,
CC       ECO:0000269|PubMed:23374343, ECO:0000269|PubMed:7782294,
CC       ECO:0000269|PubMed:9447983, ECO:0000269|PubMed:9722576}.
CC   -!- INTERACTION:
CC       P22682; Q9JLQ0: Cd2ap; NbExp=5; IntAct=EBI-640919, EBI-644807;
CC       P22682; P13379: Cd5; NbExp=5; IntAct=EBI-640919, EBI-12600513;
CC       P22682; Q01279: Egfr; NbExp=2; IntAct=EBI-640919, EBI-6296235;
CC       P22682; P39688: Fyn; NbExp=5; IntAct=EBI-640919, EBI-524514;
CC       P22682; P16056: Met; NbExp=2; IntAct=EBI-640919, EBI-1798780;
CC       P22682; Q6Q899: Rigi; NbExp=3; IntAct=EBI-640919, EBI-6841237;
CC       P22682; P00533: EGFR; Xeno; NbExp=2; IntAct=EBI-640919, EBI-297353;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Cell membrane {ECO:0000250}. Cell
CC       projection, cilium {ECO:0000269|PubMed:29237719}. Golgi apparatus
CC       {ECO:0000269|PubMed:29237719}. Note=Colocalizes with FGFR2 in lipid
CC       rafts at the cell membrane. {ECO:0000250}.
CC   -!- DOMAIN: The RING-type zinc finger domain mediates binding to an E2
CC       ubiquitin-conjugating enzyme. {ECO:0000250}.
CC   -!- DOMAIN: The N-terminus is composed of the phosphotyrosine binding (PTB)
CC       domain, a short linker region and the RING-type zinc finger. The PTB
CC       domain, which is also called TKB (tyrosine kinase binding) domain, is
CC       composed of three different subdomains: a four-helix bundle (4H), a
CC       calcium-binding EF hand and a divergent SH2 domain.
CC   -!- PTM: Phosphorylated on tyrosine residues by ALK, EGFR, FGR, INSR, SYK,
CC       FYN and ZAP70. Phosphorylated on several tyrosine residues by
CC       constitutively activated FGFR3. Phosphorylated on tyrosine residues by
CC       activated PDGFRA and PDGFRB (By similarity). Phosphorylated on tyrosine
CC       residues in response to CSF1R, FLT1 and KIT signaling. Phosphorylated
CC       on tyrosine residues by HCK. {ECO:0000250, ECO:0000269|PubMed:10092522,
CC       ECO:0000269|PubMed:15001553, ECO:0000269|PubMed:17353186,
CC       ECO:0000269|PubMed:18034775, ECO:0000269|PubMed:19265199,
CC       ECO:0000269|PubMed:7782294, ECO:0000269|PubMed:8551236,
CC       ECO:0000269|PubMed:8798454}.
CC   -!- PTM: Ubiquitinated, leading to its degradation via the proteasome.
CC       Ubiquitination is negatively regulated by IFT20.
CC       {ECO:0000250|UniProtKB:P22681}.
CC   -!- DISEASE: Note=Can be converted to an oncogenic protein by deletions or
CC       mutations that disturb its ability to down-regulate RTKs.
CC   -!- MISCELLANEOUS: This protein has one functional calcium-binding site.
CC       {ECO:0000250}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X57111; CAA40394.1; -; mRNA.
DR   EMBL; AK028730; BAC26087.1; -; mRNA.
DR   EMBL; AK153915; BAE32253.1; -; mRNA.
DR   EMBL; BC125285; AAI25286.1; -; mRNA.
DR   CCDS; CCDS40598.1; -.
DR   PIR; B43817; B43817.
DR   RefSeq; NP_031645.2; NM_007619.2.
DR   PDB; 2D9S; NMR; -; A/B=863-902.
DR   PDBsum; 2D9S; -.
DR   AlphaFoldDB; P22682; -.
DR   BMRB; P22682; -.
DR   SMR; P22682; -.
DR   BioGRID; 198527; 76.
DR   CORUM; P22682; -.
DR   DIP; DIP-33472N; -.
DR   FunCoup; P22682; 2918.
DR   IntAct; P22682; 111.
DR   MINT; P22682; -.
DR   STRING; 10090.ENSMUSP00000146244; -.
DR   GlyGen; P22682; 2 sites, 1 O-linked glycan (2 sites).
DR   iPTMnet; P22682; -.
DR   PhosphoSitePlus; P22682; -.
DR   SwissPalm; P22682; -.
DR   jPOST; P22682; -.
DR   PaxDb; 10090-ENSMUSP00000041902; -.
DR   PeptideAtlas; P22682; -.
DR   ProteomicsDB; 281225; -.
DR   Pumba; P22682; -.
DR   Antibodypedia; 3815; 1155 antibodies from 48 providers.
DR   DNASU; 12402; -.
DR   Ensembl; ENSMUST00000206720.2; ENSMUSP00000146244.2; ENSMUSG00000034342.10.
DR   GeneID; 12402; -.
DR   KEGG; mmu:12402; -.
DR   UCSC; uc009pce.1; mouse.
DR   AGR; MGI:88279; -.
DR   CTD; 867; -.
DR   MGI; MGI:88279; Cbl.
DR   VEuPathDB; HostDB:ENSMUSG00000034342; -.
DR   eggNOG; KOG1785; Eukaryota.
DR   GeneTree; ENSGT00940000155772; -.
DR   HOGENOM; CLU_013535_3_0_1; -.
DR   InParanoid; P22682; -.
DR   OMA; GCMYEAM; -.
DR   OrthoDB; 7237699at2759; -.
DR   PhylomeDB; P22682; -.
DR   Reactome; R-MMU-1059683; Interleukin-6 signaling.
DR   Reactome; R-MMU-1295596; Spry regulation of FGF signaling.
DR   Reactome; R-MMU-1433559; Regulation of KIT signaling.
DR   Reactome; R-MMU-182971; EGFR downregulation.
DR   Reactome; R-MMU-2173789; TGF-beta receptor signaling activates SMADs.
DR   Reactome; R-MMU-5654726; Negative regulation of FGFR1 signaling.
DR   Reactome; R-MMU-5654727; Negative regulation of FGFR2 signaling.
DR   Reactome; R-MMU-5654732; Negative regulation of FGFR3 signaling.
DR   Reactome; R-MMU-5654733; Negative regulation of FGFR4 signaling.
DR   Reactome; R-MMU-6807004; Negative regulation of MET activity.
DR   Reactome; R-MMU-8849469; PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1.
DR   Reactome; R-MMU-8856825; Cargo recognition for clathrin-mediated endocytosis.
DR   Reactome; R-MMU-8856828; Clathrin-mediated endocytosis.
DR   Reactome; R-MMU-912631; Regulation of signaling by CBL.
DR   Reactome; R-MMU-9706369; Negative regulation of FLT3.
DR   UniPathway; UPA00143; -.
DR   BioGRID-ORCS; 12402; 2 hits in 79 CRISPR screens.
DR   ChiTaRS; Cbl; mouse.
DR   EvolutionaryTrace; P22682; -.
DR   PRO; PR:P22682; -.
DR   Proteomes; UP000000589; Chromosome 9.
DR   RNAct; P22682; protein.
DR   Bgee; ENSMUSG00000034342; Expressed in thymus and 244 other cell types or tissues.
DR   ExpressionAtlas; P22682; baseline and differential.
DR   GO; GO:0005929; C:cilium; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0016600; C:flotillin complex; IDA:BHF-UCL.
DR   GO; GO:0005925; C:focal adhesion; IEA:Ensembl.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0030426; C:growth cone; IEA:Ensembl.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:MGI.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0046875; F:ephrin receptor binding; IPI:UniProtKB.
DR   GO; GO:0036312; F:phosphatidylinositol 3-kinase regulatory subunit binding; IEA:Ensembl.
DR   GO; GO:0001784; F:phosphotyrosine residue binding; IEA:InterPro.
DR   GO; GO:1990782; F:protein tyrosine kinase binding; IEA:Ensembl.
DR   GO; GO:0017124; F:SH3 domain binding; IPI:BHF-UCL.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IDA:MGI.
DR   GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0045453; P:bone resorption; ISS:UniProtKB.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; IEA:InterPro.
DR   GO; GO:0071456; P:cellular response to hypoxia; IEA:Ensembl.
DR   GO; GO:1990090; P:cellular response to nerve growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0036120; P:cellular response to platelet-derived growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0006974; P:DNA damage response; IEA:Ensembl.
DR   GO; GO:0008584; P:male gonad development; IEA:Ensembl.
DR   GO; GO:0043303; P:mast cell degranulation; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0042059; P:negative regulation of epidermal growth factor receptor signaling pathway; IDA:MGI.
DR   GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IEA:Ensembl.
DR   GO; GO:0048260; P:positive regulation of receptor-mediated endocytosis; ISS:UniProtKB.
DR   GO; GO:0051865; P:protein autoubiquitination; IEA:Ensembl.
DR   GO; GO:0006513; P:protein monoubiquitination; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; ISS:UniProtKB.
DR   GO; GO:0000209; P:protein polyubiquitination; IEA:Ensembl.
DR   GO; GO:0016567; P:protein ubiquitination; IDA:MGI.
DR   GO; GO:2000583; P:regulation of platelet-derived growth factor receptor-alpha signaling pathway; IMP:UniProtKB.
DR   GO; GO:0032487; P:regulation of Rap protein signal transduction; IMP:MGI.
DR   GO; GO:0014823; P:response to activity; IEA:Ensembl.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:0010332; P:response to gamma radiation; IEA:Ensembl.
DR   GO; GO:0042594; P:response to starvation; IEA:Ensembl.
DR   GO; GO:0033574; P:response to testosterone; IEA:Ensembl.
DR   GO; GO:0070086; P:ubiquitin-dependent endocytosis; IMP:MGI.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IMP:MGI.
DR   CDD; cd16708; RING-HC_Cbl; 1.
DR   CDD; cd09920; SH2_Cbl-b_TKB; 1.
DR   CDD; cd14393; UBA_c-Cbl; 1.
DR   FunFam; 1.10.238.10:FF:000022; E3 ubiquitin-protein ligase CBL; 1.
DR   FunFam; 1.10.8.10:FF:000030; E3 ubiquitin-protein ligase CBL; 1.
DR   FunFam; 1.20.930.20:FF:000001; E3 ubiquitin-protein ligase CBL; 1.
DR   FunFam; 3.30.40.10:FF:000015; E3 ubiquitin-protein ligase CBL; 1.
DR   FunFam; 3.30.505.10:FF:000154; E3 ubiquitin-protein ligase CBL; 1.
DR   Gene3D; 1.20.930.20; Adaptor protein Cbl, N-terminal domain; 1.
DR   Gene3D; 1.10.8.10; DNA helicase RuvA subunit, C-terminal domain; 1.
DR   Gene3D; 1.10.238.10; EF-hand; 1.
DR   Gene3D; 3.30.505.10; SH2 domain; 1.
DR   Gene3D; 3.30.40.10; Zinc/RING finger domain, C3HC4 (zinc finger); 1.
DR   InterPro; IPR024162; Adaptor_Cbl.
DR   InterPro; IPR014741; Adaptor_Cbl_EF_hand-like.
DR   InterPro; IPR036537; Adaptor_Cbl_N_dom_sf.
DR   InterPro; IPR003153; Adaptor_Cbl_N_hlx.
DR   InterPro; IPR014742; Adaptor_Cbl_SH2-like.
DR   InterPro; IPR024159; Cbl_PTB.
DR   InterPro; IPR011992; EF-hand-dom_pair.
DR   InterPro; IPR036860; SH2_dom_sf.
DR   InterPro; IPR015940; UBA.
DR   InterPro; IPR009060; UBA-like_sf.
DR   InterPro; IPR018957; Znf_C3HC4_RING-type.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   InterPro; IPR017907; Znf_RING_CS.
DR   PANTHER; PTHR23007; CBL; 1.
DR   PANTHER; PTHR23007:SF5; E3 UBIQUITIN-PROTEIN LIGASE CBL; 1.
DR   Pfam; PF02262; Cbl_N; 1.
DR   Pfam; PF02761; Cbl_N2; 1.
DR   Pfam; PF02762; Cbl_N3; 1.
DR   Pfam; PF00627; UBA; 1.
DR   Pfam; PF00097; zf-C3HC4; 1.
DR   SMART; SM00184; RING; 1.
DR   SMART; SM00165; UBA; 1.
DR   SUPFAM; SSF47473; EF-hand; 1.
DR   SUPFAM; SSF47668; N-terminal domain of cbl (N-cbl); 1.
DR   SUPFAM; SSF57850; RING/U-box; 1.
DR   SUPFAM; SSF55550; SH2 domain; 1.
DR   SUPFAM; SSF46934; UBA-like; 1.
DR   PROSITE; PS51506; CBL_PTB; 1.
DR   PROSITE; PS50030; UBA; 1.
DR   PROSITE; PS00518; ZF_RING_1; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
DR   TreeFam; TF314210; -.
PE   1: Evidence at protein level;
KW   3D-structure; Calcium; Cell membrane; Cell projection; Cytoplasm;
KW   Golgi apparatus; Membrane; Metal-binding; Phosphoprotein; Proto-oncogene;
KW   Reference proteome; Repeat; Transferase; Ubl conjugation;
KW   Ubl conjugation pathway; Zinc; Zinc-finger.
FT   CHAIN           1..913
FT                   /note="E3 ubiquitin-protein ligase CBL"
FT                   /id="PRO_0000055859"
FT   DOMAIN          45..349
FT                   /note="Cbl-PTB"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00839"
FT   DOMAIN          863..902
FT                   /note="UBA"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00212"
FT   ZN_FING         379..418
FT                   /note="RING-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00175"
FT   REGION          1..355
FT                   /note="Sufficient for interaction with EPHB1"
FT                   /evidence="ECO:0000269|PubMed:18034775"
FT   REGION          45..173
FT                   /note="4H"
FT   REGION          174..246
FT                   /note="EF-hand-like"
FT   REGION          247..349
FT                   /note="SH2-like"
FT   REGION          350..378
FT                   /note="Linker"
FT   REGION          356..913
FT                   /note="Required for ubiquitination of SPRED2"
FT                   /evidence="ECO:0000250|UniProtKB:P22681"
FT   REGION          430..460
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          476..613
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          646..913
FT                   /note="Interaction with CD2AP"
FT                   /evidence="ECO:0000250"
FT   REGION          647..727
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          750..787
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          814..863
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        509..521
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        531..548
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        750..770
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        771..780
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         227
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000250|UniProtKB:P22681"
FT   BINDING         229
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000250|UniProtKB:P22681"
FT   BINDING         231
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000250|UniProtKB:P22681"
FT   BINDING         233
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000250|UniProtKB:P22681"
FT   BINDING         238
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000250|UniProtKB:P22681"
FT   BINDING         292
FT                   /ligand="4-O-phospho-L-tyrosine"
FT                   /ligand_id="ChEBI:CHEBI:62338"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         369
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P22681"
FT   MOD_RES         437
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P22681"
FT   MOD_RES         450
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P22681"
FT   MOD_RES         481
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P22681"
FT   MOD_RES         617
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   MOD_RES         640
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   MOD_RES         666
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17947660"
FT   MOD_RES         667
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17947660"
FT   MOD_RES         672
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:17947660"
FT   MOD_RES         692
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   MOD_RES         698
FT                   /note="Phosphotyrosine; by ABL1"
FT                   /evidence="ECO:0000250|UniProtKB:P22681"
FT   MOD_RES         737
FT                   /note="Phosphotyrosine; by SRC"
FT                   /evidence="ECO:0000250|UniProtKB:P22681"
FT   MOD_RES         780
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P22681"
FT   MOD_RES         907
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P22681"
FT   VARIANT         364..380
FT                   /note="Missing (in oncogenic variant 70Z/3)"
FT   MUTAGEN         304
FT                   /note="G->E: Abolishes interaction with ZAP70, but does not
FT                   affect interaction with SLA."
FT                   /evidence="ECO:0000269|PubMed:12024036"
FT   CONFLICT        72..73
FT                   /note="KL -> NV (in Ref. 1; CAA40394)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        218
FT                   /note="E -> D (in Ref. 2; BAC26087)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        592
FT                   /note="P -> T (in Ref. 1; CAA40394)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        742
FT                   /note="N -> T (in Ref. 1; CAA40394)"
FT                   /evidence="ECO:0000305"
FT   HELIX           865..874
FT                   /evidence="ECO:0007829|PDB:2D9S"
FT   HELIX           878..887
FT                   /evidence="ECO:0007829|PDB:2D9S"
FT   TURN            888..890
FT                   /evidence="ECO:0007829|PDB:2D9S"
FT   HELIX           892..902
FT                   /evidence="ECO:0007829|PDB:2D9S"
SQ   SEQUENCE   913 AA;  100564 MW;  22F8A5C29F0262B8 CRC64;
     MAGNVKKSSG AGGGGSGGSG AGGLIGLMKD AFQPHHHHHH LSPHPPCTVD KKMVEKCWKL
     MDKVVRLCQN PKLALKNSPP YILDLLPDTY QHLRTVLSRY EGKMETLGEN EYFRVFMENL
     MKKTKQTISL FKEGKERMYE ENSQPRRNLT KLSLIFSHML AELKGIFPSG LFQGDTFRIT
     KADAAEFWRK AFGEKTIVPW KSFRQALHEV HPISSGLEAM ALKSTIDLTC NDYISVFEFD
     IFTRLFQPWS SLLRNWNSLA VTHPGYMAFL TYDEVKARLQ KFIHKPGSYI FRLSCTRLGQ
     WAIGYVTADG NILQTIPHNK PLFQALIDGF REGFYLFPDG RNQNPDLTGL CEPTPQDHIK
     VTQEQYELYC EMGSTFQLCK ICAENDKDVK IEPCGHLMCT SCLTSWQESE GQGCPFCRCE
     IKGTEPIVVD PFDPRGSGSL LRQGAEGAPS PNYDDDDDER ADDSLFMMKE LAGAKVERPS
     SPFSMAPQAS LPPVPPRLDL LQQRAPVPAS TSVLGTASKA ASGSLHKDKP LPIPPTLRDL
     PPPPPPDRPY SVGAETRPQR RPLPCTPGDC PSRDKLPPVP SSRPGDSWLS RPIPKVPVAT
     PNPGDPWNGR ELTNRHSLPF SLPSQMEPRA DVPRLGSTFS LDTSMTMNSS PVAGPESEHP
     KIKPSSSANA IYSLAARPLP MPKLPPGEQG ESEEDTEYMT PTSRPVGVQK PEPKRPLEAT
     QSSRACDCDQ QIDSCTYEAM YNIQSQALSV AENSASGEGN LATAHTSTGP EESENEDDGY
     DVPKPPVPAV LARRTLSDIS NASSSFGWLS LDGDPTNFNE GSQVPERPPK PFPRRINSER
     KASSYQQGGG ATANPVATAP SPQLSSEIER LMSQGYSYQD IQKALVIAHN NIEMAKNILR
     EFVSISSPAH VAT
//
